- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Vizient Says It Supports FDA Plan for Insulin Biosimilars, Interchangeable Insulins
The guidance document provides recommendations as to whether—and when—comparative clinical immunogenicity studies will be needed to support an application to the FDA for insulin products under the biosimilar approval pathway.
Vizient said this week it endorses the FDA’s draft guidance for industry on clinical immunogenicity considerations for biosimilar insulins and interchangeable insulins.
The guidance document provides recommendations as to whether—and when—comparative clinical immunogenicity studies will be needed to support an application to the FDA for insulin products under the biosimilar approval pathway.
In March, insulins will be regulated as biologics, and as such, developers will be able to seek licensure for subsequent-entry insulins under the biosimilar approval pathway after that time, whereas they are currently treated as follow-ons.
In a statement, Vizient said it believes FDA’s the guidance will support a more effective and efficient approval process by streamlining clinical data requirements.
“Vizient fully supports scientifically justified opportunities to improve approval processes for biosimilars and interchangeable biologics, including insulins,” Steven Lucio, Vizient’s vice president, pharmacy solutions, said in a statement.
“The approval of more insulin biosimilars will enable patients with diabetes to have much needed access to more affordable treatment options,” he added; the change will create more competion and lower healthcare spending.
In its comment on the draft, Vizient wrote that the FDA's approach is justified "given the strength of analytical characterization data, the less complex structure of insulin, and the absence of a clinical impact of immunogenicity with insulin use."
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.
